对于中度至重度亚托邦性皮炎患者的Cendakimab:一项随机临床试验
Andrew Blauvelt1, Emma Guttman-Yassky2, Charles Lynde3
1Oregon Medical Research Center, Portland, Oregon.
JAMA dermatology
|July 17, 2024
概括
针对介素-13的Cendakimab在中度至重度的亚托皮性皮炎患者的湿疹区域和严重性指数得分降低方面表现出显著的有效性. 每周720毫克的剂量达到主要终点,表明有前途的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 临床试验 临床试验
背景情况:
- 亚托皮炎 (AD) 是一种慢性炎症性皮肤疾病,由2型细胞因子驱动,特别是互白素-13 (IL-13).
- 仙达基马布是一种选择性IL-13抑制剂,旨在向AD病变发生过程中的这一关键途径.
研究的目的:
- 评估仙达基马布的疗效和安全性与安慰剂相比,在中度至重度AD的成年患者中.
- 为了确定最佳的剂量和治疗方案,在AD. cendakimab治疗.
主要方法:
- 一个2期,随机,双盲,安慰剂控制,剂量范围的试验,涉及221名中度至重度AD的成年患者.
- 患者接受皮下仙达基马布 (360毫克每2周,每2周720毫克或每周720毫克) 或安慰剂16周.
- 主要结局指标是从基线到第16周的湿疹区域和严重性指数 (EASI) 评分的平均百分比变化.
主要成果:
- 达基马布每周720毫克剂量达到主要疗效终点,与安慰剂相比,EASI得分显著降低 (-84.4%对-62.7%,P=.003).
- 虽然每两周服用720毫克的剂量接近显著性 (P=.06),但每两周服用360毫克的剂量显示出与每周高剂量相似的效果,尽管由于分层测试,统计学意义没有被声称.
- 导致停止治疗的不良事件在所有治疗手臂中都很低.
结论:
- 仙达基马布,特别是每周720毫克的剂量,显示出显著的疗效,并且在中度至重度阿尔茨海默病患者中通常是安全和耐受良好.
- 这项研究支持cendaakimab作为一种有效的治疗选择,用于治疗类型2炎症性疾病,如阿托皮性皮肤炎.
- 进一步的研究和剂量优化可能会提高其治疗特性.
更多相关视频
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...